Advanced Biomed EV/EBIT

Co robi Advanced Biomed? Advanced Biomed, Inc. generates revenue through the sale of assay products and services for cancer patients, including early screening, diagnosis, staging, treatment selection, and patient outcome interventions. The company's microfluidic technology platform integrates R&D, design, and manufacturing of biochips, leveraging patented chip technology and semiconductor-based biosensors. Key products include the A+Pre, AC-1000, A+CellScan, and A+SCDrop devices, paired with corresponding microfluidic biochips such as A+Pre-Chip, AC-1000 CTC Enrichment Chip, and A+CellScan Chip, which are sold to healthcare providers and research institutions. The company targets healthcare providers and research institutions seeking advanced diagnostic tools for cancer care. Its microfluidic platform enables localized operations of various microfluidic chips and biosensors, supporting applications in early cancer detection and personalized treatment strategies. Revenue streams are derived from both device sales and service offerings, with a focus on integrating semiconductor fabrication technology into medical diagnostics. Advanced Biomed's product portfolio centers on biochip-based solutions for cancer diagnostics, with devices like A+Pre and AC-1000 designed for specific clinical applications. The firm's revenue model combines the sale of proprietary devices and biochips with service-based interventions, ensuring comprehensive support for cancer patient management from screening to treatment outcomes. Healthcare providers and research institutions are the primary buyers of these integrated diagnostic solutions. Advanced Biomed jest jedną z najpopularniejszych firm na Eulerpool.